- Trials with a EudraCT protocol (1,289)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (58)
1,289 result(s) found for: Coagulation.
Displaying page 1 of 65.
EudraCT Number: 2008-001872-54 | Sponsor Protocol Number: ARC1779−006 | Start Date*: 2009-01-24 | |||||||||||
Sponsor Name:Archemix Corp | |||||||||||||
Full Title: A Randomized, Double−blind, Placebo−controlled, Clinical Outcome Study of ARC1779 Injection in Patients with Thrombotic Microangiopathy. | |||||||||||||
Medical condition: Thrombotic microangiopathy (TMA) disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018086-12 | Sponsor Protocol Number: BI1412_2009 | Start Date*: 2010-08-23 | ||||||||||||||||||||||||||
Sponsor Name:Athena Care/ Isala Klinieken | ||||||||||||||||||||||||||||
Full Title: Efficacy and safety of Haemocomplettan® P in patients experiencing microvascular bleeding while undergoing elective complex cardiac surgery | ||||||||||||||||||||||||||||
Medical condition: Elective complex cardiac surgery is associated with excessive blood loss due to coagulopathy. Fibrinogen concentrate has been shown to reverse dilutional coagulopathy. In this double blinded, place... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000740-21 | Sponsor Protocol Number: LEX-210 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor. | |||||||||||||
Medical condition: Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005650-54 | Sponsor Protocol Number: MD2011.01 | Start Date*: 2012-06-04 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||||||||||||
Full Title: Prothrombin complex concentrate in the reduction of blood loss during otrhotopic liver transplantation. | ||||||||||||||||||||||||||||
Medical condition: liver cirhosis coagulopathy bleeding | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FI (Prematurely Ended) NL (Completed) BE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002727-38 | Sponsor Protocol Number: OMS721-HCT-002 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||||||||||||
Full Title: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant... | |||||||||||||||||||||||
Medical condition: Thrombotic microangiopathies following haematopoietic stem cell transplant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Completed) NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002873-35 | Sponsor Protocol Number: LEO 90010-I21 | Start Date*: 2007-04-24 | ||||||||||||||||
Sponsor Name:LEO Pharmaceutical Products Ltd A/S (LEO Pharma A/S) | ||||||||||||||||||
Full Title: Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis | ||||||||||||||||||
Medical condition: Disseminated intravascular coagulation associated with severe sepsis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) FR (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000246-19 | Sponsor Protocol Number: 3-3002 | Start Date*: 2018-09-24 | ||||||||||||||||
Sponsor Name:Asahi Kasei Pharma America Corporation | ||||||||||||||||||
Full Title: SCARLET-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Sepsis and Coagulopathy | ||||||||||||||||||
Medical condition: Sepsis, defined by the presence of infection and host inflammation, is a lethal clinical syndrome. In severe disease, the coagulation system becomes diffusely activated, with consumption of multipl... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002035-81 | Sponsor Protocol Number: 2-001 | Start Date*: 2007-10-22 | ||||||||||||||||
Sponsor Name:Artisan Pharma, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation | ||||||||||||||||||
Medical condition: Sepsis and disseminated intravascular coagulation. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000382-19 | Sponsor Protocol Number: BE1116_3001 | Start Date*: 2005-09-15 | |||||||||||
Sponsor Name:ZLB Behring GmbH | |||||||||||||
Full Title: Efficacy and tolerance of BERIPLEX® P/N in subjects with acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation | |||||||||||||
Medical condition: Acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation requiring an immediate reversal of anticoagulant effect (i.e. emergency surgery or acute bleeding). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) HU (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004484-31 | Sponsor Protocol Number: Riva-PCC | Start Date*: 2014-01-10 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck / Allg. u. chirug. Intensivmedizin | |||||||||||||
Full Title: Rivaroxaban and PCC: Prothrombin Complex Concentrate in patients with bleeding complications related to Rivaroxaban | |||||||||||||
Medical condition: blood coagulation disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005350-29 | Sponsor Protocol Number: 2013-03-612 | Start Date*: 2014-02-14 | |||||||||||
Sponsor Name:Rigshospitalet [...] | |||||||||||||
Full Title: Effect of Human Albumin versus crystalloid on coagulation competence during elective urologic surgery. | |||||||||||||
Medical condition: Coagulation and loss of blood | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000444-22 | Sponsor Protocol Number: NL75930.078.20 | Start Date*: 2021-04-07 |
Sponsor Name:Erasmus MC | ||
Full Title: Differences in coagulation between fresh frozen plasma and Solventdetergent plasma in pediatric congenital heart surgery | ||
Medical condition: coagulation in pediatric cardiac surgery | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001265-17 | Sponsor Protocol Number: 3.0 | Start Date*: 2018-08-07 |
Sponsor Name:Turku University Central Hospital | ||
Full Title: Relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis (EdoRot). | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007862-39 | Sponsor Protocol Number: BE1116_3003 | Start Date*: 2009-01-16 | ||||||||||||||||
Sponsor Name:CSL Behring GmbH | ||||||||||||||||||
Full Title: An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by vitamin K an... | ||||||||||||||||||
Medical condition: Perioperative prophylaxis for emergency surgery in subjects who have an acquired deficiency of vitamin K-dependent coagulation factors and proteins C and S | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000026-44 | Sponsor Protocol Number: 2007-04-04 | Start Date*: 2007-04-19 | ||||||||||||||||
Sponsor Name:Aarhus Universityhospital | ||||||||||||||||||
Full Title: Hydroxyethylstarch induced coagulopathy and haemostatic potential of fibrinogen - in vivo placebo controlled clinical trial. | ||||||||||||||||||
Medical condition: The present study evaluates dilution coagulopathy induced by hydroxyethyl starch solutions in a clinical setting on patients undergoeing cystektomia due to bladder cancer. Furteher the haemostatic ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001282-13 | Sponsor Protocol Number: AGO/2015/004 | Start Date*: 2015-06-30 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Evaluation of acute normovolemic hemodilution on coagulation during liver surgery. | ||
Medical condition: coagulation during liver surgery Acute normowolemic hemodilution | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003148-51 | Sponsor Protocol Number: F13CD-1725 | Start Date*: 2008-08-15 | |||||||||||||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||||||||||||
Full Title: A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII ... | |||||||||||||||||||||||
Medical condition: Congenital Factor XIII Deficiency | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) FR (Completed) DE (Completed) AT (Completed) ES (Completed) FI (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-007883-41 | Sponsor Protocol Number: F13CD-3720(Mentor™2) | Start Date*: 2009-08-13 | |||||||||||||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||||||||||||
Full Title: A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Deficiency | |||||||||||||||||||||||
Medical condition: Congenital Factor XIII Deficiency | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FI (Completed) DE (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003321-99 | Sponsor Protocol Number: ANES002 | Start Date*: 2012-03-02 |
Sponsor Name:UZ Brussels | ||
Full Title: Comparison of Volulyte® versus Tetraspan® in patients undergoing cardiopulmonary bypass. | ||
Medical condition: coagulation status, colloid oncotic pressure (COP) and ion- and acid-base balance. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000156-42 | Sponsor Protocol Number: NL35250.008.10 | Start Date*: 2011-04-19 |
Sponsor Name:Amphia Hospital | ||
Full Title: Effect of the plasma substitutes Gelofusine and Hydroxyethyl Starch 130/0.4 combined with lactated ringer's solution on the coagulation system | ||
Medical condition: A standard component of the priming which is used in extra corporal circulation is the synthetic colloïd Gelofusine (Braun, Melsung AG, Germany). Because of logistical reasons and cost saving the q... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
